Jefferies Group’s Myriad Genetics MYGN Stock Holding History

Jefferies Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17,500	Closed	-$486K	–	2915
2019 Q2	$486K	Sell	17,500 -73,100	-81%	-$2.06M	﹤0.01%	1685
2019 Q1	$3.01M	Buy	+90,600	New	+$2.76M	0.02%	684
2016 Q1	–	Sell	-10,000	Closed	-$432K	–	2453
2015 Q4	$432K	Hold	10,000	–	–	﹤0.01%	1607
2015 Q3	$375K	Hold	10,000	–	–	﹤0.01%	1647
2015 Q2	$340K	Hold	10,000	–	–	﹤0.01%	1733
2015 Q1	$354K	Sell	10,000 -39,300	-80%	-$1.41M	﹤0.01%	1528
2014 Q4	$1.68M	Buy	+49,300	New	+$1.75M	0.01%	780
2014 Q2	–	Sell	-210,600	Closed	-$7.2M	–	2278
2014 Q1	$7.2M	Buy	210,600 +187,600	+816%	+$5.81M	0.07%	225
2013 Q4	$483K	Buy	+23,000	New	+$582K	﹤0.01%	1164
2013 Q3	–	Sell	-54,400	Closed	-$1.46M	–	2098
2013 Q2	$1.46M	Buy	+54,400	New	+$1.58M	0.02%	631

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's MYGN Position: Q2 2019 in Review

Jefferies Group sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 85,131 shares — an estimated $2.4M sold.

Jefferies Group first reported a position in MYGN in Q2 2013 and held it in 12 quarters. The position peaked at $2.83M in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Jefferies Group reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Jefferies Group sold 85,131 Myriad Genetics shares in Q2 2019, an estimated $2.4M.
Jefferies Group first reported a position in Myriad Genetics in Q2 2013 and held it in 12 quarters.
Jefferies Group's Myriad Genetics position peaked at $2.83M in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.